NCT02091908 - Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions | Biotech Hunter

Enrollment

540

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

Influenza, Human

Interventions

BIOLOGICAL

Novartis Investigational H5N1 vaccine

2 doses of 0.5 ml, 3 weeks apart

BIOLOGICAL

Novartis Investigational H5N1 vaccine

2 doses of 0.5 ml, 3 weeks apart

BIOLOGICAL

Novartis Seasonal Influenza Vaccine

2 doses of 0.5 ml, 3 weeks apart

BIOLOGICAL

Novartis Seasonal Influenza Vaccine

2 doses of 0.5 ml, 3 weeks apart

Trial Locations (6)

001, Novartis Investigational Site, Berlin

004, Novartis Investigational Site, Rostock

005, Novartis Investigational Site, Hamburg

006, Novartis Investigational Site, Magdeburg

002, Novartis Investigational Site, Würzburg

003, Novartis Investigational Site, Dresden